基于生物标志物的房颤患者心衰风险评估:COMBINE-AF 分析
该研究汇总 3 项大型随机试验中 32,041 例房颤患者的个体数据,评估 NT-proBNP、hs-cTnT 和 GDF-15 对心衰风险的增量预后价值。调整临床因素和所有生物标志物后,三者均与心血管死亡或心衰住院显著相关,且加入生物标志物后临床模型区分度从 0.70 提升至 0.77。
要点
- NT-proBNP、hs-cTnT 和 GDF-15 独立且显著改善房颤患者心衰风险分层。
- hs-cTnT 对心衰风险分层的贡献与 NT-proBNP 相当。
- 生物标志物加入临床模型后 c-index 从 0.70 升至 0.77。
核心结论
- NT-proBNP、hs-cTnT 和 GDF-15 对房颤患者心衰终点风险分层有显著独立贡献,hs-cTnT 与 NT-proBNP 同等重要。
- 研究支持未来使用这些生物标志物区分房颤患者心衰低风险或高风险。
研究设计与样本
- 汇总 COMBINE-AF 队列中 3 项比较 DOAC 与华法林的大型随机试验(ARISTOTLE、ENGAGE AF-TIMI 48、RE-LY)的个体患者数据。
- 纳入基线有可用生物标志物的全部患者,共 32,041 例。
- 复合终点为心衰住院(HHF)或心血管死亡(CVD),次要终点为 HHF 和心衰相关死亡。
- 采用 Cox 回归调整临床因素,并用加权分位数和回归分析处理生物标志物间相关性。
主要发现
- 生物标志物值越高,CVD/HHF、HHF 和心衰相关死亡的绝对风险呈梯度增加。
- 调整临床变量和所有生物标志物后,NT-proBNP(每 1 SD 的 HR:1.68;95%CI:1.59-1.77)、hs-cTnT(HR:1.39;95%CI:1.33-1.44)和 GDF-15(HR:1.20;95%CI:1.15-1.25)均与 CVD/HHF 显著相关。
- 加入生物标志物后临床模型区分度显著改善(c-index:0.70 [95%CI:0.69-0.71] 至 0.77 [95%CI:0.76-0.78];似然比检验 P < 0.001)。
- 加权分位数和回归分析显示,NT-proBNP 和 hs-cTnT 对 CVD/HHF 风险评估的贡献相似(分别为 38% 和 41%),GDF-15 贡献较小但具有统计学显著性。
- HHF 和心衰相关死亡单独分析结果相似,且在有心衰病史、房颤类型和左室射血分数降低或保留的关键亚组中结果一致。
临床怎么用
- 可考虑检测 NT-proBNP、hs-cTnT 和 GDF-15 以改善房颤患者的心衰风险分层。
- hs-cTnT 对心衰风险分层的价值与 NT-proBNP 相当,提示两者可联合或互补使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Heart failure (HF) is common among patients with atrial fibrillation (AF), and accurate risk assessment is clinically important. OBJECTIVES: The goal of this study was to investigate the incremental prognostic performance of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high-sensitivity cardiac troponin T (hs-cTnT), and growth differentiation factor (GDF)-15 for HF risk stratification in patients with AF. METHODS: Individual patient data from 3 large randomized trials comparing direct oral anticoagulants (DOACs) with warfarin (ARISTOTLE [Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation], ENGAGE AF-TIMI 48 [Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis In Myocardial Infarction 48], and RE-LY [Randomized Evaluation of Long-Term Anticoagulation Therapy]) from the COMBINE-AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonist Oral Anticoagulant Use in Atrial Fibrillation) cohort were pooled; all patients with available biomarkers at baseline were included. The composite endpoint was hospitalization for HF (HHF) or cardiovascular death (CVD), and secondary endpoints were HHF and HF-related death. Cox regression was used, adjusting for clinical factors, and interbiomarker correlation was addressed using weighted quantile sum regression analysis. RESULTS: In 32,041 patients, higher biomarker values were associated with a graded increase in absolute risk for CVD/HHF, HHF, and HF-related death. Adjusting for clinical variables and all biomarkers, NT-proBNP (HR per 1 SD: 1.68; 95% CI: 1.59-1.77), hs-cTnT (HR: 1.39; 95% CI: 1.33-1.44), and GDF-15 (HR: 1.20; 95% CI: 1.15-1.25) were significantly associated with CVD/HHF. The discrimination of the clinical model improved significantly upon addition of the biomarkers (c-index: 0.70 [95% CI: 0.69-0.71] to 0.77 [95% CI: 0.76-0.78]; likelihood ratio test, P < 0.001). Using weighted quantile sum regression analysis, the contribution to risk assessment was similar for NT-proBNP and hs-cTnT for CVD/HHF (38% and 41%, respectively); GDF-15 provided a statistically significant but lesser contribution to risk assessment. Results were similar for HHF and HF-related death, individually, and across key subgroups of patients based on a history of HF, AF pattern, and reduced or preserved left ventricular ejection fraction. CONCLUSIONS: NT-proBNP, hs-cTnT, and GDF-15 contributed significantly and independently to the risk stratification for HF endpoints in patients with AF, with hs-cTnT being as important as NT-proBNP for HF risk stratification. Our findings support a possible future use of these biomarkers to distinguish patients with AF at low or high risk for HF.
引用
- Haller, Jarolim, Palazzolo, et al. Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF. J Am Coll Cardiol. 2024. PMID: 39230543. doi:10.1016/j.jacc.2024.07.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。